Morgans lifts Pro Medicus to buy on steady flow of contract wins
Morgans analyst Iain Wilkie upgrades Pro Medicus to buy from accumulate, citing steady modest contract wins. Target price stays at A$230.00.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Morgans analyst Iain Wilkie has upgraded Australian medical-technology provider Pro Medicus to buy from accumulate. Market Talk reports that in a note to clients he sees a steady run of modest contract wins as evidence of a repeatable mid-market model.
According to Wilkie, this model is widening the company's opportunity pipeline. He noted three new community health deals so far in FY 2027, which he called a steady start to the period. Morgans keeps its target price at 230.00 Australian dollars.
At the time of reporting, shares were up 0.2% at A$178.01.
why it matters
The signal concerns a single company in the medical software sector. The higher rating reflects the analyst's view of the business but does not guarantee any move in the share price. Markets typically respond modestly to notes like this, especially when they focus on smaller contracts.
tags
instruments
sources
- Pro Medicus Bull Hails Steady Flow of Wins — Market Talk, 19 October 2026 at 23:53 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗